{"id":"W2659827805","doi":"10.1200/jco.2017.35.15_suppl.e12538","title":"Real world experience with exemestane and everolimus for advanced HR-positive breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Exemestane; Everolimus; Internal medicine; Metastatic breast cancer; Breast cancer; Cohort; Oncology; Adverse effect; Population; Cancer; Progression-free survival; Toxicity; Letrozole; Aromatase inhibitor; Chemotherapy; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007214122,0.0001688057,0.001297263,0.00006980031,0.0001799683,0.00001974636,0.000220559,0.0001443994,0.00004598563],"category_scores_gemma":[0.0005955244,0.0001115654,0.0001759074,0.00005114543,0.0008338769,0.0003909888,0.00005378771,0.0005223156,7.645157e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002062002,"about_ca_system_score_gemma":0.001083088,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007693442,"about_ca_topic_score_gemma":0.000413691,"domain_scores_codex":[0.9980661,0.00007521534,0.001055176,0.0002563092,0.0002587778,0.000288378],"domain_scores_gemma":[0.9953505,0.0009842234,0.002213257,0.0003059529,0.0007381422,0.0004079204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.06205582,0.0004218306,0.1547267,0.0000383069,0.0003763649,0.0004623601,0.0004726999,0.00001735884,0.001013203,0.0002393836,0.0001099878,0.780066],"study_design_scores_gemma":[0.01920623,0.009166507,0.9497355,0.00047778,0.0002928101,0.00152715,0.0003256385,0.00004202107,0.000329961,0.0005552138,0.01818363,0.0001575318],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979849,0.0005032959,0.0009626646,0.0158588,0.0008610622,0.0003936681,0.00002752327,0.00001208201,0.00153191],"genre_scores_gemma":[0.9774411,0.001345123,0.01777879,0.001317559,0.00134615,0.00003463674,8.965949e-7,0.00002765295,0.0007080461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7950088,"threshold_uncertainty_score":0.4549505,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08937730650384973,"score_gpt":0.5096555776797362,"score_spread":0.4202782711758865,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}